IN8BIO, INC. Operating Lease Liability
IN8BIO, INC. (INAB) had Operating Lease Liability of $2.05 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability $2.05M.
- 2026-03-31: Operating Lease, Liability $2.17M.
- 2025-12-31: Operating Lease, Liability $2.49M.
- 2025-09-30: Operating Lease, Liability $2.55M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $2.05M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.17M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.49M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.55M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.59M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.51M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $4.04M 10-K · filed 2025-03-13 |
| 2024-09-30 | $4.26M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $4.48M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $4.68M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $3.67M 10-K · filed 2024-03-14 |
| 2023-09-30 | $3.85M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.03M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $4.21M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $4.38M 10-K · filed 2023-03-30 |
| 2022-09-30 | $4.49M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $1.58M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $1.74M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.75M 10-K · filed 2022-03-17 |
| 2021-09-30 | $1.76M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $833.00K 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |